Get the Stockscreener App
24.30
2.75%
0.65
Dianthus Therapeutics Inc stock is traded at $24.30, with a volume of 366.76K.
It is up +2.75% in the last 24 hours and up +17.16% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$23.65
Open:
$23.82
24h Volume:
366.76K
Relative Volume:
1.13
Market Cap:
$782.18M
Revenue:
$4.12M
Net Income/Loss:
$-56.68M
P/E Ratio:
-4.384
EPS:
-5.5429
Net Cash Flow:
$-51.44M
1W Performance:
+17.16%
1M Performance:
+17.16%
6M Performance:
+2.66%
1Y Performance:
-12.02%
1-Day Range:
$22.76
$25.01
1-Week Range:
$20.31
$25.01
52-Week Range:
$13.37
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
24.30 | 674.67M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Heatmap analysis for Dianthus Therapeutics Inc. and competitorsJuly 2025 Intraday Action & High Yield Stock Recommendations - Newser
Will Dianthus Therapeutics Inc. stock go up soon2025 Top Gainers & Smart Allocation Stock Tips - Newser
Volatility clustering patterns for Dianthus Therapeutics Inc.Trade Analysis Summary & Reliable Price Breakout Alerts - Newser
Q3 EPS Estimate for Dianthus Therapeutics Reduced by Analyst - MarketBeat
What earnings revisions data tells us about Dianthus Therapeutics Inc.Chart Signals & Daily Momentum Trading Reports - Newser
Has Dianthus Therapeutics Inc. formed a bullish divergenceRate Hike & Risk Managed Investment Entry Signals - Newser
What data driven models say about Dianthus Therapeutics Inc.’s futureJuly 2025 Review & Technical Pattern Recognition Alerts - Newser
Using R and stats models for Dianthus Therapeutics Inc. forecastingWeekly Market Report & Growth Focused Stock Reports - Newser
Visualizing Dianthus Therapeutics Inc. stock with heatmapsMarket Activity Recap & Stepwise Entry and Exit Trade Signals - Newser
Applying Elliott Wave Theory to Dianthus Therapeutics Inc.July 2025 Review & Daily Technical Forecast Reports - Newser
Dianthus Therapeutics Inc.’s volatility index tracking explained2025 Risk Factors & Technical Buy Zone Confirmations - Newser
Backtesting results for Dianthus Therapeutics Inc. trading strategiesWeekly Profit Summary & Verified Entry Point Detection - Newser
Using fundamentals and technicals on Dianthus Therapeutics Inc.Quarterly Earnings Summary & Entry Point Confirmation Alerts - Newser
Can trapped investors hope for a rebound in Dianthus Therapeutics Inc.2025 Institutional Moves & Long Hold Capital Preservation Plans - Newser
Published on: 2025-08-19 06:16:57 - Newser
Elliott Wave Theory Predicts Pullback in Dianthus Therapeutics Inc.2025 Bull vs Bear & Consistent Income Trade Recommendations - Newser
Cantor Fitzgerald Issues Negative Outlook for DNTH Earnings - MarketBeat
Custom watchlist performance reports with Dianthus Therapeutics Inc.Jobs Report & Risk Controlled Swing Alerts - Newser
Relative strength of Dianthus Therapeutics Inc. in sector analysisJuly 2025 Spike Watch & Daily Market Momentum Tracking - Newser
Published on: 2025-08-17 17:07:03 - Newser
Can Dianthus Therapeutics Inc. recover in the next quarter2025 Major Catalysts & Real-Time Sentiment Analysis - Newser
Can you recover from losses in Dianthus Therapeutics Inc.Exit Point & Momentum Based Trading Ideas - Newser
Is Dianthus Therapeutics Inc. stock poised for growthPortfolio Return Report & Consistent Income Trade Ideas - Newser
Is Dianthus Therapeutics Inc. a potential multi baggerMarket Sentiment Report & Verified Swing Trading Watchlists - thegnnews.com
HC Wainwright Issues Pessimistic Estimate for DNTH Earnings - MarketBeat
Is Dianthus Therapeutics Inc. stock showing strong momentumQuarterly Portfolio Report & Fast Entry and Exit Trade Plans - thegnnews.com
Equities Analysts Issue Forecasts for DNTH Q1 Earnings - MarketBeat
Lifesci Capital Issues Negative Outlook for DNTH Earnings - Defense World
Dianthus Therapeutics Inc. stock trendline breakdownWeekly Risk Report & Verified Entry Point Signals - Newser
Published on: 2025-08-15 16:22:59 - Newser
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):